Exit
Siegfried Holding acquires Noramco, Extractas and Purisys from SK Capital
SK Capital will retain ownership of Halo Pharmaceuticals, a finished-dose-form CDMO in the US and Canada.
SK Capital has exited its controlled-substances pharmaceutical platform, selling Noramco, Extractas Biosciences, and Purisys to Swiss contract development and manufacturing organization Siegfried Holding.
The private equity firm retains Halo Pharmaceuticals, a North American finished-dose CDMO.
Deal facts
- Target
- Noramco, Extractas Biosciences and Purisys
- Buyer
- Siegfried Holding
- Seller
- SK Capital Partners
- Deal type
- Exit
- Status
- Completed
- Announced
- Monday, May 4, 2026
Sources
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.